Lung cancer and HIV

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

BACKGROUND: People, living with HIV, have a greater chance of malignancies especially with the success of antiretroviral therapy, and non-AIDS-defining cancers have become the most common cause of death after AIDS and the most common of them is the lung cancer in developed countries.

AIM: To research nosological characteristics of lung cancer in the context of HIV infection, HIV-associated risk factors during antiretroviral therapy and compare with global trends of this problem.

MATERIALS AND METHODS: Retrospectively were analyzed the medical documentation of 98 patients with lung cancer and HIV-infection, who were in database and received specialized treatment in Saint Petersburg from 2008 to 2018 years.

RESULTS: The population was dominated by patients of young (1844 years old) and middle (4559 years old) ages, 45.9% and 42.9%, respectively, and 11.2% of elderly patients (6074 years old), p <0.001, which satisfies the global data of earlier incidence of lung cancer in people living with HIV.

Adenocarcinomas were more common histological subtype of lung cancer as in the general population (p <0.001).

There was no static significance between high viral load and lung cancer, which can indicate the absence of a direct mechanism of HIV-carcinogenesis (90.8% of patients with low and medium viral load, p <0.001). Nevertheless, the prevalence of 4-stage of HIV infection among lung cancer patients (p <0.001) indicates a history of inflammatory diseases, including pulmonary diseases, as a result of induced immunosuppression due to CD8+-lymphocyte dysfunction and the formation of a micro-tumor environment, which can be a prognostic unfavorable factor in the occurrence of lung cancer in this group of patients , as well as indirect mechanism of viral carcinogenesis.

The presence of elderly patients (11.2%, MAX71 years) indirectly indicates an increasing of period of life expectancy among this category of patients in Russia.

CONCLUSION: The mechanisms of increased risk of lung cancer among HIV-infected people remain largely unclear and can be the area for active research. HIV-infected patients with lung cancer are younger than HIV-negative patients and have more advanced stages of cancer with a prevalence of adenocarcinoma type of cancer. The lung cancer prognosis of survival in HIV-infected people is much worse than that of persons without HIV-infection, but it is not fully known whether this is due to a more aggressive course of the disease, disparities in treatment, treatment resistance, or a greater risk and toxicity of therapy.

Full Text

Restricted Access

About the authors

Georgy M. Manikhas

Petersburg State Medical University

Email: manikhas.g@mail.ru
ORCID iD: 0000-0002-2569-1683

MD, Dr. Sci. (Med.), Professor

Russian Federation, 6-8 Lev Tolstoy street,197022 Saint Petersburg

Alexander A. Zakharenko

Petersburg State Medical University

Email: 9516183@mail.ru
ORCID iD: 0000-0002-9520-8271

MD, Dr. Sci. (Med.), Professor

Russian Federation, 6-8 Lev Tolstoy street,197022 Saint Petersburg

Dmitry A. Polezhaev

Petersburg State Medical University; City Clinical Oncology Dispensary

Email: polezhaevdm@gmail.com
ORCID iD: 0000-0002-1725-2015
SPIN-code: 5953-9370

Cand. Sci. (Med.), Associate Professor

Russian Federation, 6-8 Lev Tolstoy street,197022 Saint Petersburg; 56 Veteranov avenue, 198255 Saint Petersburg

Alexandr M. Panteleev

Center for the Prevention and Control of AIDS and Infectious Diseases

Email: alpanteleev@gmail.com
ORCID iD: 0000-0001-8940-9758
SPIN-code: 2577-3295

MD, Dr. Sci. (Med.), Professor

Russian Federation, Saint Petersburg

Denis A. Gusev

Center for the Prevention and Control of AIDS and Infectious Diseases

Email: gavrilovpsonk@gmail.com
ORCID iD: 0000-0001-9202-3231
SPIN-code: 3343-3375

MD, Dr. Sci. (Med.), Professor

Russian Federation, Saint Petersburg

Olga V. Panteleeva

Petersburg State Medical University; City Tuberculosis Hospital N 2

Email: gavrilovpsonk@gmail.com
SPIN-code: 7575-5120

MD, Cand. Sci. (Med.)

Russian Federation, 6-8 Lev Tolstoy street,197022 Saint Petersburg; Saint Petersburg

Alexey R. Zakirov

Petersburg State Medical University

Email: Lexazakirov2196@gmail.com
ORCID iD: 0000-0002-9349-2571
SPIN-code: 8812-2980
Russian Federation, 6-8 Lev Tolstoy street,197022 Saint Petersburg

Pavel S. Gavrilov

Petersburg State Medical University; City Clinical Oncology Dispensary

Author for correspondence.
Email: gavrilovpsonk@gmail.com
ORCID iD: 0000-0002-6011-0303
SPIN-code: 7308-9050

PhD, Student

Russian Federation, 6-8 Lev Tolstoy street,197022 Saint Petersburg; 56 Veteranov avenue, 198255 Saint Petersburg

References

  1. Kaprin AD, Starinskii VV, Petrova GV, editors. Malignant neoplasms in Russia in 2015 (morbidity and mortality). Moscow: P.A.Herzen Moscow Research Institute of Oncology; 2017. (In Russ).
  2. Panteleeva OV. Epidemiological situation on HIV infection in women and children in St. Petersburg [Internet]. Saint Petersburg; 2019. Available from: https://congress-ph.ru/common/htdocs/upload/fm/vich/19/15-03-2019/prez/02.pdf (In Russ)
  3. Thrift AP, Kramer JR, Hartman CM, et al. Risk and predictors of esophageal and stomach cancers in HIV-infected veterans: a matched cohort study. J Acquir Immune Defic Syndr. 2019;81(3):e65–e72. doi: 10.1097/QAI.0000000000002038
  4. Wang CJ, Sparano J, Palefsky JM. Human immunodeficiency virus/AIDS, human papillomavirus, and anal cancer. Surg Oncol Clin N Am. 2017;26(1):17–31. doi: 10.1016/j.soc.2016.07.010
  5. Bedimo RJ, McGinnis KA, Dunlap M, et al. Incidence of non-AIDS-defining malignancies in HIV-infected versus noninfected patients in the HAART era: impact of immunosuppression. J Acquir Immune Defic Syndr. 2009;52(2):203–208. doi: 10.1097/QAI.0b013e3181b033ab
  6. Shiels MS, Islam JY, Rosenberg PS, et al. Projected cancer incidence rates and burden of incident cancer cases in HIV-infected adults in the United States through 2030. Ann Intern Med. 2018;168(12):866–873. doi: 10.7326/M17-2499
  7. Hoffman C, Rockstroh JK. HIV [Internet]. Germany, 2015. Available from: https://www.hivbuch.de/wp-content/uploads/2020/12/HIV2015-16_GB.pdf
  8. Smith CJ, Ryom L, Weber R, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet. 2014;384(9939):241–248. doi: 10.1016/S0140-6736(14)60604-8
  9. Zakharova NG, Dvorak SI, Guba ZV, et al. The causes of unfavorable outcomes among patients taking HAART. Part 2. HIV Infection and Immunosuppressive Disorders. 2015;7(4):52–63. doi: 10.22328/2077-9828-2015-7-4-5-8
  10. Worm SW, Bower M, Reiss P, et al. Non-AIDS defining cancers in the D:A:D study-time trends and predictors of survival: a cohort study. BMC Infect Dis. 2013;13:471. doi: 10.1186/1471-2334-13-471
  11. Irwin LE, Begandy MK, Moore TM. Adenosquamous carcinoma of the lung and the acquired immunodeficiency syndrome. Ann Intern Med. 1984.100(1):158. doi: 10.7326/0003-4819-100-1-158_2
  12. Engels EA, Goedert JJ. Human immunodeficiency virus/acquired immunodeficiency syndrome and cancer: past, present, and future. J Natl Cancer Inst. 2005;97(6):407–409. doi: 10.1093/jnci/dji085
  13. Engels EA, Brock MV, Chen J, et al. Elevated incidence of lung cancer among HIV-infected individuals. J Clin Oncol. 2006;24(9):1383–1388. doi: 10.1200/JCO.2005.03.4413
  14. Cadranel J, Garfield D, Layole A, et al. Lung cancer in HIV infected patients: facts, questions and challenges. Thorax. 2006;61(11):1000–1008. doi: 10.1136/thx.2005.052373
  15. Rihana N, Nanjappa S, Sullivan C, et al. Malignancy trends in HIV-infected patients over the past 10 years in a single-center retrospective observational study in the United States. Cancer Control. 2018;25(1). doi: 10.1177/1073274818797955
  16. Marcus JL, Chao CR, Leyden WA, et al. Narrowing the Gap in Life Expectancy Between HIV-Infected and HIV-Uninfected Individuals With Access to Care. J Acquir Immune Defic Syndr. 2016;73(1):39-46. doi: 10.1097/QAI.0000000000001014
  17. Sigel K, Makinson A, Thaler J. Lung cancer in persons with HIV. Curr Opin HIV AIDS. 2017;12(1):31–38. doi: 10.1097/COH.0000000000000326
  18. Beck JM, Schloss PD, Venkataraman A, et al. Multicenter comparison of lung and oral microbiomes of HIV-infected and HIV-uninfected individuals. Am J Respir Crit Care Med. 2015;192(11):1335–1344. doi: 10.1164/rccm.201501-0128OC
  19. Twigg HL 3rd, Knox KS, Zhou J, et al. Effect of advanced HIV infection on the respiratory microbiome. Am J Respir Crit Care Med. 2016;194(2):226–235. doi: 10.1164/rccm.201509-1875OC
  20. Barkan SE, Melnick SL, Preston-Martin S, et al. The Women’s Interagency HIV Study. WIHS Collaborative Study Group. Epidemiology. 1998;9(2):117–125.
  21. Kaslow RA, Ostrow DG, Detels R, et al. The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol. 1987;126(2):310–318. doi: 10.1093/aje/126.2.310
  22. Hleyhel M, Hleyhel M, Bouvier AM, et al. Risk of non-AIDS-defining cancers among HIV-1-infected individuals in France between 1997 and 2009: results from a French cohort. AIDS. 2014;28(14):2109–2118. doi: 10.1097/QAD.0000000000000382
  23. Sigel K, Crothers K, Gordon K, et al. Proceedings of the Conference on Retroviruses and Opportunistic Infections. 2015 Feb. Seattle, Washington, USA. Abstract 110
  24. Twigg HL, Soliman DM, Day RB, et al. Lymphocytic alveolitis, bronchoalveolar lavage viral load, and outcome in human immunodeficiency virus infection. Am J Respir Crit Care Med. 1999;159(5 Pt 1): 1439–1444. doi: 10.1164/ajrccm.159.5.9808031
  25. Brune KA, Ferreira F, Mandke P, et al. HIV impairs lung epithelial integrity and enters the epithelium to promote chronic lung inflammation. PLoS One. 2016;11(3):e0149679. doi: 10.1371/journal.pone.0149679
  26. Mait-Kaufman J, Fakioglu E, Mesquita PM, et al. Chronic HIV infection is associated with upregulation of proinflammatory cytokine and chemokine and alpha defensin gene expression in colorectal mucosa. AIDS Res Hum Retroviruses. 2015;31(6):615–622. doi: 10.1089/AID.2014.0085
  27. Popescu I, Drummond MB, Gama L. Activation-induced cell death drives profound lung CD4(+) T-cell depletion in HIV-associated chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2014;190(7):744–755. doi: 10.1164/rccm.201407-1226OC
  28. Cribbs SK, Lennox J, Caliendo AM, et al. Healthy HIV-1-infected individuals on highly active antiretroviral therapy harbor HIV-1 in their alveolar macrophages. AIDS Res Hum Retroviruses. 2015;31(1):64–70. doi: 10.1089/AID.2014.0133
  29. Almodovar S. The complexity of HIV persistence and pathogenesis in the lung under antiretroviral therapy: challenges beyond AIDS. Viral Immunol. 2014;27(5):186–199. doi: 10.1089/vim.2013.0130
  30. Geffen N, Aagaard P, Corbelli GM, et al. International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) Community Advisory Board. Community perspective on the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med. 2015;16(S1):10–13. doi: 10.1111/hiv.12228
  31. Bruyand M, Ryom L, Shepherd L, et al. Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: the D: A: D study. J Acquir Immune Defic Syndr. 2015;68(5):568–577. doi: 10.1097/QAI.0000000000000523
  32. Marcus JL, Chao C, Leyden WA, et al. Survival among HIV-infected and HIV-uninfected individuals with common non-AIDS-defining cancers. Cancer Epidemiol Biomarkers Prev. 2015;24(8):1167–1173. doi: 10.1158/1055-9965.EPI-14-1079
  33. Stevens JR, Al Masud A, Suyundikov A. A comparison of multiple testing adjustment methods with block-correlation positively-dependent tests. PLoS One. 2017;12(4):e0176124. doi: 10.1371/journal.pone.0176124
  34. Lanoy E, Spano JP, Bonnet F, et al. ONCOVIH study group — the spectrum of malignancies in HIV-infected patients in 2006 in France: the ONCOVIH study. Int J Cancer. 2011;129(2):467–475. doi: 10.1002/ijc.25903
  35. Shiels MS, Engels EA. Evolving epidemiology of HIV-associated malignancies. Curr Opin HIV AIDS. 2017;12(1):6–11. doi: 10.1097/COH.0000000000000327
  36. Reddy KP, Kong CY, Hyle EP, et al. Lung cancer mortality associated with smoking and smoking cessation among people living with HIV in the United States. JAMA Intern Med. 2017;177(11):1613–1621. doi: 10.1001/jamainternmed.2017
  37. Crequit P, Ruppert AM, Rozensztajn N, et al. EGFR and KRAS mutation status in non-small-cell lung cancer occurring in HIV-infected patients. Lung Cancer. 2016;96:74–77. doi: 10.1016/j.lungcan.2015.11.021
  38. Kirk GD, Merlo C, O’Driscoll P, et al. HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis. 2007;45(1):103–110. doi: 10.1086/518606

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2022 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС 77 - 86496 от 11.12.2023 г. 
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ЭЛ № ФС 77 - 80673 от 23.03.2021 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies